PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 1, 1999Journal of Clinical Oncology962 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

View Full Paper
JPJoachim von PawelJSJoan H. SchillerFSFrances A. Shepherd

Key Points

Key points are not available for this paper at this time.

Abstract

Topotecan was at least as effective as CAV in the treatment of patients with recurrent SCLC and resulted in improved control of several symptoms.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Pawel et al. (1999) studied this question.

synapsesocial.com/papers/69d98e7a387cf706986847e7https://doi.org/10.1200/jco.1999.17.2.658
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.1996 · 40 citations
  2. 2126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study1997 · 64 citations
  3. 3Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.1995 · 175 citations
  4. 4Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.1987 · 81 citations
  5. 538 Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy1997 · 21 citations